DK1263464T3 - Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion - Google Patents

Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion

Info

Publication number
DK1263464T3
DK1263464T3 DK01956188.5T DK01956188T DK1263464T3 DK 1263464 T3 DK1263464 T3 DK 1263464T3 DK 01956188 T DK01956188 T DK 01956188T DK 1263464 T3 DK1263464 T3 DK 1263464T3
Authority
DK
Denmark
Prior art keywords
tgf
prevention
treatment
renal impairment
antagonist anti
Prior art date
Application number
DK01956188.5T
Other languages
English (en)
Inventor
Steven R Ledbetter
Richard J Roman
Original Assignee
Genzyme Corp
Mcw Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22691635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1263464(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Mcw Res Foundation filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK1263464T3 publication Critical patent/DK1263464T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
DK01956188.5T 2000-03-09 2001-03-08 Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion DK1263464T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18806000P 2000-03-09 2000-03-09
PCT/US2001/007473 WO2001066140A1 (en) 2000-03-09 2001-03-08 Use of tgf-beta antagonists to treat or to prevent loss of renal function

Publications (1)

Publication Number Publication Date
DK1263464T3 true DK1263464T3 (da) 2013-01-28

Family

ID=22691635

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01956188.5T DK1263464T3 (da) 2000-03-09 2001-03-08 Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion

Country Status (10)

Country Link
EP (1) EP1263464B1 (da)
JP (1) JP2004502644A (da)
AU (1) AU2001272100A1 (da)
CA (1) CA2400628A1 (da)
DK (1) DK1263464T3 (da)
ES (1) ES2398039T3 (da)
HK (1) HK1047542A1 (da)
IL (2) IL151369A0 (da)
PT (1) PT1263464E (da)
WO (1) WO2001066140A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
MXPA04002575A (es) * 2001-09-20 2004-06-18 Schering Corp Quimiocinas como adyuventes de respuesta inmune.
US20060286105A1 (en) * 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
WO2006069417A1 (en) * 2004-12-31 2006-07-06 The University Of Queensland A method of treatment
CA2606778A1 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Vascular disease therapies
WO2007040636A1 (en) * 2005-09-29 2007-04-12 Fibrogen, Inc. Methods for reducing blood pressure
ITMI20060181A1 (it) * 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
PT2012814E (pt) 2006-04-12 2013-07-18 Genzyme Corp Métodos de tratamento de doenças auto-imunes
EP2035835B1 (en) * 2006-05-30 2011-12-28 Antibodyshop A/S Methods for rapid assessment of severity of a trauma
JP2009539842A (ja) * 2006-06-05 2009-11-19 ノバルティス アクチエンゲゼルシャフト 副甲状腺関連障害の処置におけるＴＧＦ−βアンタゴニストの使用
DK2262520T3 (da) 2008-02-26 2017-08-07 Univ Cornell Sammensætninger til forebyggelse og behandling af nyreskader
US20140309167A1 (en) * 2011-11-09 2014-10-16 Universita ; Degli Studi Bari Combination of active ingredients for the treatment of acute kidney injury
ES2417679B1 (es) * 2011-12-09 2014-09-15 Servicio Andaluz De Salud Prevención y tratamiento de las lesiones renales asociadas a la litiasis renal de la vía urinaria.
EP3459598A1 (en) 2012-12-06 2019-03-27 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
PL2971048T4 (pl) 2013-03-11 2019-05-31 Genzyme Corp Zmodyfikowane przeciwciała anty-TGF-beta i fragmenty wiążące antygen
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
CA2950410A1 (en) 2014-05-28 2015-12-03 D. Travis Wilson Therapeutic compositions including therapeutic small molecules and uses thereof
EP3501532A3 (en) 2014-05-28 2019-07-17 Stealth BioTherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
BR112019023071A2 (pt) 2017-05-04 2020-06-09 Acceleron Pharma Inc proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
KR20230024249A (ko) * 2020-03-11 2023-02-20 우니베르지테트 베른 신장 장애의 치료를 위한 페투인 a
KR20240082377A (ko) 2021-09-30 2024-06-10 페프티드림 아이엔씨. 펩티드
CN117531016A (zh) * 2023-11-24 2024-02-09 华中科技大学同济医学院附属同济医院 NRP1和TGF-βR抑制剂组合在制备肾损伤治疗药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0775742A3 (en) 1989-09-29 1998-01-14 La Jolla Cancer Research Foundation Inhibiting transforming growth factor beta to prevent accumulation of axtracellular matrix
ZA914750B (en) * 1990-06-20 1992-03-25 Bristol Myers Squibb Co Methods of modulating blood pressure using tgf-beta and antagonists thereof
AU6984594A (en) 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
JPH08333249A (ja) * 1995-06-07 1996-12-17 Ono Pharmaceut Co Ltd ＴＧＦ−β放出、活性化および合成抑制剤
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
NZ508317A (en) * 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease

Also Published As

Publication number Publication date
IL151369A (en) 2013-08-29
AU2001272100A1 (en) 2001-09-17
CA2400628A1 (en) 2001-09-13
EP1263464B1 (en) 2012-10-31
ES2398039T3 (es) 2013-03-13
WO2001066140A1 (en) 2001-09-13
HK1047542A1 (zh) 2003-02-28
EP1263464A1 (en) 2002-12-11
PT1263464E (pt) 2012-12-17
IL151369A0 (en) 2003-04-10
JP2004502644A (ja) 2004-01-29

Similar Documents

Publication Publication Date Title
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DE60204827D1 (de) Anhebungsdetektion zur automatischen Sprachzusammenfassung
DE60126838D1 (de) Amidoacetonitrile zur Bekämpfung von Endoparasiten
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1263503T3 (da) Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1411926T3 (da) Integrininhibitorer til behandling af öjensygdomme
DK199800837A (da) Anlæg til behandling af emner
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK3103443T3 (da) Fremgangsmåde til behandling af primær søvnforstyrrelse
EP1445096A4 (en) IMPACT-RESISTANT FILM
NO20005023D0 (no) FremgangsmÕter for Õ hemme MRP1
DK1268482T3 (da) Pyranoindoler til behandling af glaukom